Doxazosin inhibits retinoblastoma protein phosphorylation and G1→S transition in human coronary smooth muscle cells

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 20, Issue 5, 2000, Pages 1216-1224

  Kintscher, Ulrich ^a,b,c   Wakino, Shu ^a   Kim, Sarah ^a   Jackson, Simon M ^a   Fleck, Eckart ^b,c   Hsueh, Willa A ^a   Law, Ronald E ^a,d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b HUMBOLDT UNIVERSITY   (Germany)

^c DEUTSCHES HERZZENTRUM BERLIN   (Germany)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cell cycle; Doxazosin; Proliferation; Retinoblastoma; Vascular smooth muscle cells

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; CYCLIN A; CYCLIN DEPENDENT KINASE INHIBITOR; DOXAZOSIN; INSULIN; MITOGENIC AGENT; PHENOXYBENZAMINE; PLATELET DERIVED GROWTH FACTOR; PROTEIN P27; RETINOBLASTOMA PROTEIN; TERAZOSIN; TRANSCRIPTION FACTOR E2F;

ANIMAL CELL; ARTERY MUSCLE; ARTICLE; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL PROLIFERATION; CELL STRAIN 3T3; CONTROLLED STUDY; CORONARY ARTERY; DRUG MECHANISM; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; MITOGENESIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

EID: 0034023213     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.20.5.1216     Document Type: Article

References (42)

1. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 1993;362:801-809.
2. Braun-Dullaeus RC, Mann MJ, Dzau VJ. Cell cycle progression: new therapeutic target for vascular proliferative disease. Circulation. 1998;98: 82-89.
3. Sherr CJ. G1 phase progression: cycling on cue. Cell. 1994;79:551-555.
4. Girard F, Strausfeld U, Fernandez A, Lamb NJ. Cyclin A is required for the onset of DNA replication in mammalian fibroblasts. Cell. 1991;67: 1169-1179.
5. Morgan DO. Principles of CDK regulation. Nature. 1995;374:131-134.
6. Weinberg RA. The retinoblastoma protein and cell cycle control. Cell. 1995;81:323-330.
7. Nevins JR, Leone G, DeGregori J, Jakoi L. Role of the Rb/E2F pathway in cell growth control. J Cell Physiol. 1997;173:233-236.
8. Takahashi A, Taniguchi T, Ishikawa Y, Yokoyama M. Tranilast inhibits vascular smooth muscle cell growth and intimai hyperplasia by induction of p21(waf1/cip1/sdi1) and p53. Circ Res. 1999;84:543-550.
9. Gallo R, Padurean A, Jayaraman T, Marx S, Roque M, Adelman S, Chesebro J, Fallon J, Fuster V, Marks A, Badimon JJ. Inhibition of intimai thickening after balloon angioplasty in porcine coronary arteries by targeting regulators of the cell cycle. Circulation. 1999;99: 2164-2170.
10. Hu ZW, Shi XY, Hoffman BB. Doxazosin inhibits proliferation and migration of human vascular smooth-muscle cells independent of alpha1-adrenergic receptor antagonism. J Cardiovasc Pharmacol. 1998;31: 833-839.
11. Vashisht R, Sian M, Franks PJ, O'Malley MK. Long-term reduction of intimai hyperplasia by the selective alpha-1 adrenergic antagonist doxazosin. Br J Surg. 1992;79:1285-1288.
12. Xiao G, MacLellan R. E2F regulates c-myc expression in ventricular cardiac myocytes. Circulation. 1999;100(suppl I):I-634. Abstract.
13. Goetze S, Xi XP, Kawano H, Gotlibowski T, Fleck E, Hsueh WA, Law RE. PPAR gamma-ligands inhibit migration mediated by multiple chemoaltractants in vascular smooth muscle cells. J Cardiovasc Pharmacol. 1999;33:798-806.
14. Connell-Crowley L, Harper JW, Goodrich DW. Cyclin D1/Cdk4 regulates retinoblastoma protein-mediated cell cycle arrest by site-specific phosphorylation. Mol Biol Cell. 1997;8:287-301.
15. Driscoll B, T'Ang A, Hu YH, Yan CL, Fu Y, Luo Y, Wu KJ, Wen S, Shi XH, Barsky L, Weinberg K, Murphree AL, Fung YK. Discovery of a regulatory motif that controls the exposure of specific upstream cyclin-dependent kinase sites that determine both conformation and growth suppressing activity of pRb. J Biol Chem. 1999;274:9463-9471.
16. Schulze A, Zerfass K, Spitkovsky D, Middendorp S, Berges J, Helin K, Jansen-Durr P, Henglein B. Cell cycle regulation of the cyclin A gene promoter is mediated by a variant E2F site. Proc Natl Acad Sci U S A. 1995;92:11264-11268.
17. Toyoshima H, Hunter T. p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21. Cell. 1994;78:67-74.
18. Polyak K, Lee MH, Erdjument-Bromage H, Koff A, Roberts JM, Tempst P, Massague J. Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell. 1994;78:59-66.
19. Rao GN. Differential regulation of p27 kip1 levels and CDK activities by hypertrophic and hyperplastic agents in vascular smooth muscle cells. Biochim Biophys Acta. 1999;1448:525-532.
20. Johnson DG, Schwarz JK, Cress WD, Nevins JR. Expression of transcription factor E2F1 induces quiescent cells to enter S phase. Nature. 1993;365:349-352.
21. Tsai TJ, Lin RH, Chang CC, Chen YM, Chen CF, Ko FN, Teng CM. Vasodilator agents modulate rat glomerular mesangial cell growth and collagen synthesis. Nephron. 1995;70:91-99.
22. Knudsen ES, Wang JY. Differential regulation of retinoblastoma protein function by specific Cdk phosphorylation sites. J Biol Chem. 1996;271: 8313-8320.
23. Morishita R, Gibbons GH, Horiuchi M, Ellison KE, Nakama M, Zhang L, Kaneda Y, Ogihara T, Dzau VJ. A gene therapy strategy using a transcription factor decoy of the E2F binding site inhibits smooth muscle proliferation in vivo. Proc Natl Acad Sci U S A. 1995;92:5855-5859.
24. Lundberg AS, Weinberg RA. Functional inactivation of the retinoblastoma protein requires sequential modification by at least two distinct cyclin-cdk complexes. Mol Cell Biol. 1998;18:753-761.
25. Braun-Dullaeus RC, Mann MJ, Ziegler A, von der Leyen HE, Dzau VJ. A novel role for the cyclin-dependent kinase inhibitor p27(Kip1) in angiotensin II-stimulated vascular smooth muscle cell hypertrophy. J Clin Invest. 1999;104:815-823.
26. Coats S, Flanagan WM, Nourse J, Roberts JM. Requirement of p27Kip1 for restriction point control of the fibroblast cell cycle. Science. 1996; 272:877-880.
27. Nourse J, Firpo E, Flanagan WM, Coats S, Polyak K, Lee MH, Massague J, Crabtree GR, Roberts JM. Interleukin-2-mediated elimination of the p27Kip1 cyclin-dependent kinase inhibitor prevented by rapamycin. Nature. 1994;372:570-573.
28. Laufs U, Marra D, Node K, Liao JK. 3-Hydroxy-3-methylglutaryl-CoA reductase inhibitors attenuate vascular smooth muscle proliferation by preventing rho GTPase-induced down-regulation of p27(Kip1). J Biol Chem. 1999;274:21926-21931.
29. Shirane M, Harumiya Y, Ishida N, Hirai A, Miyamoto C, Hatakeyama S, Nakayama K, Kitagawa M. Down-regulation of p27(Kip1) by two mechanisms, ubiquitin-mediated degradation and proteolytic processing. J Biol Chem. 1999;274:13886-13893.
30. Pagano M, Tam SW, Theodoras AM, Beer-Romero P, Del Sal G, Chau V, Yew PR, Draetta GF, Rolfe M. Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science. 1995;269:682-685.
31. Rao S, Porter DC, Chen X, Herliczek T, Lowe M, Keyomarsi K. Lovastatin-mediated G1 arrest is through inhibition of the proteasome, independent of hydroxymethyl glutaryl-CoA reductase. Proc Natl Acad Sci U S A. 1999;96:7797-7802.
32. Hinds PW, Mittnacht S, Dulic V, Arnold A, Reed SI, Weinberg RA. Regulation of retinoblastoma protein functions by ectopic expression of human cyclins. Cell. 1992;70:993-1006.
33. Dynlacht BD, Flores O, Lees JA, Harlow E. Differential regulation of E2F transactivation by cyclin/cdk2 complexes. Genes Dev. 1994;8: 1772-1786.
34. Kato JY, Matsuoka M, Polyak K, Massague J, Sherr CJ. Cyclic AMP-induced G1 phase arrest mediated by an inhibitor (p27Kip1) of cyclin-dependent kinase 4 activation. Cell. 1994;79:487-496.
35. Wu J, Dent P, Jelinek T, Wolfman A, Weber MJ, Sturgill TW. Inhibition of the EGF-activated MAP kinase signaling pathway by adenosine 3′,5′-monophosphate. Science. 1993;262:1065-1069.
36. Graves LM, Bornfeldt KE, Raines EW, Potts BC, Macdonald SG, Ross R, Krebs EG. Protein kinase A antagonizes platelet-derived growth factor-induced signaling by mitogen-activated protein kinase in human arterial smooth muscle cells. Proc Natl Acad Sci U S A. 1993;90:10300-10304.
37. Lavoie JN, L'Allemain G, Brunet A, Muller R, Pouyssegur J. Cyclin D1 expression is regulated positively by the p42/p44 MAPK and negatively by the p38/HOGMAPK pathway. J Biol Chem. 1996;271:20608-20616.
38. van Kleef EM, Smits JF, Schwartz SM, Daemen MJ. Doxazosin blocks the angiotensin II-induced smooth muscle cell DNA synthesis in the media, but not in the neointima of the rat carotid artery after balloon injury. Cardiovasc Res. 1996;31:324-330.
39. Chang MW, Barr E, Seltzer J, Jiang YQ, Nabel GJ, Nabel EG, Parmacek MS, Leiden JM. Cytostatic gene therapy for vascular proliferative disorders with a constitutively active form of the retinoblastoma gene product. Science. 1995;267:518-522.
40. Tanner FC, Yang ZY, Duckers E, Gordon D, Nabel GJ, Nabel EG. Expression of cyclin-dependent kinase inhibitors in vascular disease. Circ Res. 1998;82:396-403.
41. Wei GL, Krasinski K, Kearney M, Isner JM, Walsh K, Andres V. Temporally and spatially coordinated expression of cell cycle regulatory factors after angioplasty. Circ Res. 1997;80:418-426.
42. Frick MH, Halttunen P, Himanen P, Huttunen M, Porsti P, Pitkajarvi T, Poyhonen L, Pyykonen ML, Reinikainen P, Salmela P, et al. A long-term double-blind comparison of doxazosin and atenolol in patients with mild to moderate essential hypertension. Br J Clin Pharmacol. 1986;21: 55S-62S.